Marcia Angell: Drug Co & Doctors: A Story of Corruption

"It is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgment of trusted physicians or authoritative medical guidelines. I take no pleasure in this conclusion, which I reached slowly and reluctantly over my two decades as an editor of The New England Journal of Medicine." Marcia Angell, MD Continue reading →

Biederman J & J Risperdal Documents

A group of internal emails by Johnson & Johnson officials-mostly from officials in the company’s Risperdal marketing division-provide a bird’s eye view of collusion between the drug giant and Harvard’s leading child psychiatrist, Dr. Joseph Biederman, and one of Harvard’s premier teaching hospitals, Massachusetts General Hospital.
Continue reading →

Vera Sharav: A Profile in Nature Biotechnology

Dr. Marcia Angell, a senior lecturer at Harvard Medical School, and former editor of the New England Journal of Medicine and author of The Truth About Drug Companies, describes Sharav as an extraordinarily observant and valuable critic.   "I see her as someone the research establishment badly needs."

Continue reading →

Public Furor Forces NYU to Pull Ransom Note Ad Campaign

Good news but continued vigilance required! A backlash by outraged parents and advocates for responsible evidence-based rhetoric about physical and mental health issues, forced Dr. Harold Koplewicz, founder and director of the NYU Child Study Center, to pull the irresponsible, fear mongering . . . Continue reading →

Grassley Probes COI at American Psychiatric Association

Sen. Grassley is peeling away psychiatry’s layers of deception about the efficacy and safety of its treatments: "I have come to understand that money from the pharmaceutical industry can shape the practices of nonprofit organizations that purport to be independent in their viewpoints and actions."
Continue reading →

Letter of Complaint Re: FDA Double Agent


A follow-up letter to FDA Commissioner, Andrew vonEschenbach RE: Thomas Laughren, FDA’s ‘s Director of Psychiatry Products who has been actively promoting psychotropic drugs–even penning his name to ghostwritten industry-sponsored articles and consensus panels.  Continue reading →